Signaling pathway-focused gene expression profiling in pressure overloaded hearts

Area of Science:

• Cardiovascular biology
• Molecular pharmacology
• Cardiac remodeling

Background:

• Beta-blockers like propranolol have known antihypertrophic and antifibrotic effects in the heart.
• The precise molecular mechanisms underlying propranolol's beneficial actions in pressure-overloaded hearts are not fully elucidated.

Purpose of the Study:

• To investigate the gene expression profile related to propranolol's antihypertrophic effects.
• To identify specific signaling pathways influenced by propranolol in pressure-overloaded mouse hearts.

Main Methods:

• Utilized a real-time PCR array to analyze 84 gene transcripts across 18 signaling pathways.
• Assessed gene expression in left ventricular tissue of mice subjected to transverse aortic constriction (TAC) or sham surgery.
• Administered propranolol or vehicle for 14 days post-surgery.

Main Results:

• Transverse aortic constriction (TAC) increased left ventricular weight-to-body weight ratio by 49% without altering gene expression.
• Propranolol treatment blunted the TAC-induced increase in heart size by approximately 50%.
• Propranolol significantly upregulated Brca1 (TGF-beta pathway) and Cdkn2a (estrogen pathway) gene expression.

Conclusions:

• Pressure overload alone did not significantly alter the cardiac gene expression profile after two weeks.
• Propranolol treatment in pressure-overloaded hearts was associated with increased expression of cell cycle-inhibiting genes.
• Further research is needed to confirm a direct mechanistic link between these gene expression changes and propranolol's antihypertrophic action.